Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial

Denham, James W.; Steigler, Allison; Lamb, David; Joseph, David; Mameghan, Hedy; Turner, Sandra; Matthews, John; Franklin, Ian M.; Atkinson, Callum; North, J. B.; Poulsen, Michael; Christie, David; Spry, Nigel; Tai, Keen‐Hun; Wynne, Chris; Duchesne, Gillian; Kovacev, Olga; DʼEste, Catherine

doi:10.1016/s1470-2045(05)70348-x

Cited by 356 publications

(281 citation statements)

References 29 publications

Supporting

Mentioning

256

Contrasting

Unclassified

Order By: Relevance

“…[6][7][8] The clinical significance of the current study is for men who have prostate cancer with Gleason scores from 8 to 10, for which the accepted standards of care are to administer from 6 months to 3 years of HT with RT based on the results of prospective randomized trials. 1,2,4,5 The results of the current study provide evidence to support the use of the duration of AS after 6 months of HT as a way to identify men who have prostate cancer with Gleason scores from 8 to 10 who may achieve the cancer-specific survival benefit associated with longer term use of HT. 5 Specifically, as illustrated in Figure 1, of the 51 men who had prostate cancer with Gleason scores from 8 to 10, the 5-year estimates of PCSM were 0% in 19 men and 38% in 32 men if the duration of testosterone suppression (6 months of HT administration plus the duration of AS) was 2 years compared with 2 years, respectively.…”

Section: Discussionmentioning

confidence: 57%

Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy

D’Amico

Renshaw

Loffredo

et al. 2007

Cancer

View full text Add to dashboard Cite

Supercritical emulsion extraction (SEE) was recently proposed for the production of biopolymer microparticles starting from oil‐in‐water emulsions. This technology can improve the product quality because of the fast and selective extraction of the dispersed oily phase by using supercritical carbon dioxide (SC‐CO2). However, until now, SEE was proposed in batch configuration, sharing with the traditional processes an intrinsically discontinuous operation and problems of batches reproducibility and process yield. In this study, by using a countercurrent packed column, the SEE process was proposed in a continuous operating mode (SEE‐CM) for the production of poly‐lactic‐co‐glycolic acid (PLGA) microparticles. The new process design takes advantage of the large contact area between the SC‐CO2 and emulsion allowing the production of PLGA microparticles with controlled and narrow size distributions in only few minutes. SEE‐CM operating parameters such as pressure, temperature, and flow rate ratios were analyzed and the process efficiency in terms of recovered material and its size distribution compared with SEE (batch mode operation) and conventional evaporation technology. PLGA microparticles showed a mean particle size between 1–3 µm (depending on the droplet sizes) with a SD that was always smaller than that associated with particles produced by discontinuous processes. Single and double emulsions were successfully treated and the microparticles physico‐chemical properties showed no morphological and structural differences between the SEE‐CM‐produced microparticles and the ones obtained by conventional evaporation technology. Biotechnol. Bioeng. 2011; 108:676–686. © 2010 Wiley Periodicals, Inc.

show abstract

Section: Discussionmentioning

confidence: 57%

Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy

D’Amico

Renshaw

Loffredo

et al. 2007

Cancer

View full text Add to dashboard Cite

show abstract

“…Randomized trials have shown that RT + AD improves survival over RT alone (43)(44)(45)(46). The results, however, are far from optimal.…”

Section: Discussionmentioning

confidence: 99%

Antisense-MDM2 Sensitizes LNCaP Prostate Cancer Cells to Androgen Deprivation, Radiation, and the Combination In Vivo

Stoyanova

Hachem

Hensley

et al. 2007

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Purpose-To test the effects of antisense (AS)-MDM2 alone and with androgen deprivation (AD), radiotherapy (RT), and AD + RT on wild-type LNCaP cells in an orthotopic in vivo model. Methods-Androgen-sensitiveLNCaP cells were grown in the prostates of nude mice. Magnetic resonance imaging-based tumor volume and serum prostate-specific antigen (PSA) measurements were used to assess effects on tumor response. Tumor response was measured by biochemical and tumor volume failure definitions and doubling time estimates from fitted PSA and tumor volume growth curves. Expression of MDM2, p53, p21, and Ki-67 was quantified using immunohistochemical staining and image analysis of formalin-fixed tissue, analogous to methods used clinically.Results-Antisense-MDM2 significantly inhibited the growth of LNCaP tumors over the mismatch controls. The most significant increase in tumor growth delay and tumor doubling time was from AS-MDM2 + AD + RT, although the effect of AS-MDM2 + AD was substantial. Expression of MDM2 was significantly reduced by AS-MDM2 in the setting of RT.Conclusions-This is the first in vivo investigation of the effects of AS-MDM2 in an orthotopic model and the first to demonstrate incremental sensitization when added to AD and AD + RT. The results with AD underscore the potential to affect micrometastatic disease, which is probably responsible for treatment failure in 30-40% of men with high-risk disease.

show abstract

“…Several Phase III studies have demonstrated that combination of AST and radiotherapy is better than radiotherapy alone [2][3][4][5][6][13][14][15][16][17][18][19][20][21].…”

Section: The Combination Of Adt and Radiotherapy Is Better Than Radiothmentioning

confidence: 99%

The Use of Androgen Deprivation in Conjunction with Radiation in Localized Prostate Cancer

Mahmoud¹,

Abdel‐Wahab²

2010

TOPCANJ

View full text Add to dashboard Cite

Abstract:Background: In prostate carcinoma, there is controversy about optimal use of hormonal therapy with external beam radiotherapy: who will benefit, for how long, neo-adjuvant versus concurrent versus adjuvant. Patients and Methods:Evidence from randomized studies in the light of recent published articles and updates were reviewed in order to address these issues. Results and Conclusions:From this review it was concluded that the benefit of long-term hormonal therapy in combination with conventional-dose radiotherapy (<74 Gy) in high-risk prostate cancer is evident. For the intermediate risk, the evidence is still weak and studies are awaited to clarify this matter.

show abstract

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial

Cited by 356 publications

References 29 publications

Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy

Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy

Antisense-MDM2 Sensitizes LNCaP Prostate Cancer Cells to Androgen Deprivation, Radiation, and the Combination In Vivo

The Use of Androgen Deprivation in Conjunction with Radiation in Localized Prostate Cancer

Contact Info

Product

Resources

About